Donitriptan

Donitriptan
Clinical data
ATC code	None;
Legal status
Legal status	Never marketed;
Identifiers
	IUPAC name 4-[4-({[3-(2-Aminoethyl)-1H-indol-5-yl]oxy}acetyl)-1-piperazinyl]benzonitrile;
CAS Number	170912-52-4;
PubChem CID	197706;
ChemSpider	171128;
UNII	70968BVH2J;
ChEMBL	ChEMBL1742428;
CompTox Dashboard (EPA)	DTXSID20168974 ;
Chemical and physical data
Formula	C23H25N5O2
Molar mass	403.486 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc(ccc1C#N)N2CCN(CC2)C(=O)COc3ccc4c(c3)c(c[nH]4)CCN;
	InChI InChI=1S/C23H25N5O2/c24-8-7-18-15-26-22-6-5-20(13-21(18)22)30-16-23(29)28-11-9-27(10-12-28)19-3-1-17(14-25)2-4-19/h1-6,13,15,26H,7-12,16,24H2; Key:SOHCKWZVTCTQBG-UHFFFAOYSA-N;

Donitriptan (INN; code name F-11356) is a triptan drug which was investigated as an antimigraine agent but ultimately was never marketed.^[1] It acts as a high-affinity, high-efficacy/near-full agonist of the 5-HT_1B (pK_i = 9.4–10.1; IA = 94%) and 5-HT_1D receptors (pK_i = 9.3–10.2; IA = 97%), and is among the most potent of the triptan series of drugs.^[2]^[3]^[4] Donitriptan was being developed in France by bioMérieux-Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued.^[5]^[6]^[7]

Quick Facts Clinical data, ATC code ...

References